Boehringer Ingelheim Announces Leadership Changes in Shareholders’ Committee and Board
The Shareholders’ Committee of Boehringer Ingelheim have announced the following appointments in the Shareholders’ Committee and the Board of Managing Directors: Christian Boehringer, Chairman of the Shareholders’ Committee since 2007, has decided to step down from his position as of June 30, 2025. The Shareholders' Committee has appointed Hubertus von Baumbach, currently Chairman of the Board of Directors, as his successor from July 1, 2025.
Shashank Deshpande, member of the Board of Managing Directors, has been appointed Chairman of the Board of Managing Directors, a responsibility that he will take on in addition to his current role leading the Human Pharma Business Unit. He will take over the Chairman’s mandate from Hubertus von Baumbach per July 1, 2025.
Shashank Deshpande joined Boehringer Ingelheim in 2012, following a decade in pharma in the US. He took on various human pharma leadership positions in Germany and Japan, ultimately as Country Managing Director Japan. In 2023, Deshpande joined the Board of Managing Directors, with responsibility for Animal Health. In 2024, he was given responsibility for Human Pharma. Shashank Deshpande holds a Master’s degree in Business Administration from the University of Hamburg, Germany.
"I am thankful that the shareholders entrust me with the Chairman’s role on the Board," said Shashank Deshpande. "I want to acknowledge Hubertus’ leadership of the company these past nine years. You’ve built a great team, and it’s a true pleasure to be part of it. We are fully focused on bringing our strong pipeline to the market as fast as possible, and I am highly motivated to lead our organization to achieve this for the benefit of the patients and animals we serve.”
Hubertus von Baumbach was a member of the company management for 16 years, including nine years as Chairman. He added: "I wish Shashank much success; with his many years of industry experience in the US, Japan, and Germany, he will lead Boehringer through the next growth phase towards 2035."
